Data processing: measuring – calibrating – or testing – Measurement system in a specific environment – Biological or biochemical
Reexamination Certificate
2011-04-26
2011-04-26
Zeman, Mark K (Department: 1631)
Data processing: measuring, calibrating, or testing
Measurement system in a specific environment
Biological or biochemical
C702S020000, C703S011000, C703S012000, C707S700000, C435S006120, C536S024500
Reexamination Certificate
active
07933722
ABSTRACT:
The present invention provides methods for the assessment of diseases that result from the combined or interactive effects of two or more genetic variants, and in particular for diagnosing risk of developing such diseases in subjects using an analysis of genetic polymorphisms. Methods for the derivation of a net score indicative of a subject's risk of developing a disease are provided.
REFERENCES:
patent: 4829052 (1989-05-01), Glover et al.
patent: 5455262 (1995-10-01), Schwartz et al.
patent: 5674754 (1997-10-01), Ahrens et al.
patent: 5773430 (1998-06-01), Simon et al.
patent: 5827662 (1998-10-01), Rubin
patent: 5837492 (1998-11-01), Tavtigian
patent: 5840698 (1998-11-01), Campbell et al.
patent: 5844108 (1998-12-01), Meyer
patent: 5851983 (1998-12-01), Sugiyama et al.
patent: 5932579 (1999-08-01), Campbell et al.
patent: 5935852 (1999-08-01), Follettie
patent: 6022893 (2000-02-01), Sakaki et al.
patent: 6033857 (2000-03-01), Tavtigian
patent: 6057292 (2000-05-01), Cunningham et al.
patent: 6057297 (2000-05-01), Politi et al.
patent: 6060283 (2000-05-01), Okura
patent: 6117869 (2000-09-01), Picard et al.
patent: 6171798 (2001-01-01), Levine
patent: 6183963 (2001-02-01), Sinnett
patent: 6184022 (2001-02-01), Seiki et al.
patent: 6187587 (2001-02-01), Popoff et al.
patent: 6211209 (2001-04-01), Baragi et al.
patent: 6268142 (2001-07-01), Duff
patent: 6346385 (2002-02-01), Eguchi et al.
patent: 6387615 (2002-05-01), Cookson et al.
patent: 6610510 (2003-08-01), Valenzuela
patent: 6673549 (2004-01-01), Furness
patent: 6677442 (2004-01-01), Wang
patent: 6706478 (2004-03-01), Duff
patent: 6716581 (2004-04-01), Lenz
patent: 7054758 (2006-05-01), Gill-Garrison et al.
patent: 2002/0197646 (2002-12-01), Nogee et al.
patent: 2004/0106120 (2004-06-01), Tazi-Ahnini et al.
patent: 2004/0152124 (2004-08-01), Duff
patent: 2004/0219548 (2004-11-01), Young
patent: 2004/0241714 (2004-12-01), Branch
patent: 2005/0064454 (2005-03-01), Young
patent: 2005/0196754 (2005-09-01), Drmanac
patent: 2005/0272054 (2005-12-01), Cargill
patent: 2005/0282198 (2005-12-01), Duff
patent: 2006/0122373 (2006-06-01), Mccarthy
patent: 0 854 191 (1998-07-01), None
patent: 1 043 406 (2006-06-01), None
patent: 2005328707 (2005-12-01), None
patent: WO 02/097127 (2002-12-01), None
patent: WO 2006121351 (2006-11-01), None
patent: WO 2006123943 (2006-11-01), None
patent: WO 2006123954 (2006-11-01), None
patent: WO 2006123955 (2006-11-01), None
Barnes, “Molecular genetics of chronic obstructive pulmonary disease,”Thorax54:245-252 (1999).
Butkiewicz et al., “TSTM1, TSTP1, CYP1A1 and CYP2D6 polymorphisms in lung cancer patients from an environmentally polluted region of Poland: correlation with lung DNA adduct levels,”European Journal of Cancer Prevention, (abstract) 8:315-323 (1999).
Cambien et al., “Polymorphisms of the Transforming Growth Factor-β1 Gene in Relation to Myocardial Infarction and Blood Pressure,”Hypertension28:881-887 (1996).
Cantlay et al., “Heterogeneous express and polymorphic genotype of glutathione S-transferase in human lung,”Thorax49:1010-1014 (1994).
Dunleavey et al., “Rapid genotype analysis of the matrix metalloproteinase-1 gene 1G/2G polymorphism that is associated with risk of cancer,”Matrix Biology, 19:175-177 (2000).
Folz et al., “Elevated Levels of Extracellular Superoxide Dismutase in Chronic Lung Disease and Characterization of Genetic Variants,”Chest, 111:74S (1997).
Greisenbach et al., “Anti-inflammatory gene therapy directed at the airway epithelium,”Gene Therapy, vol. 7, No. 4, pp. 306-313 (Feb. 2000).
Harrison et al., “Frequency of glutathione S-transferase M1 deletion in smokers with emphysema and lung cancer,”Human&Experimental Toxicology16:356-360 (1997).
Hirano et al., “Tissue inhibitor of metalloproteinase-2 gene polymorphisms in chronic obstructive pulmonary disease,”European Respiratory Journal, vol. 18, pp. 748-752 (2001).
Joos et al., “The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function,”Human Molecular Genetics, vol. 11, pp. 569-576 (2002).
Jormsjö et al., “Allele-Specific Regulation of Matrix Metlaloproteinase-12 Gene Activity is Associated with Coronary Artery Luminal Dimensions in Diabetic Patients with Manifest Coronary Artery Disease,”Cir. Res. 86:998-1003 (2000).
Kalsheker et al., “Deoxyribonucleic acid (DNA) polymorphism of the a1-antitrypsin gene in chronic lung disease,”British Medical Journal, 294:1511-1514 (1987).
Marklund et al., “Two variants of extracellular-superoxide dismutase: relationship to cardiovascular risk factors in an unselected middle-aged population,”Journal of Internal Medicine, 242:5-14 (1997).
Minematsu et al. “Genetic polymorphism in Matrix Metalloproteinase-9 and pulmonary emphysema,”Biochemical and Biophysical Research Communicationvol. 289, pp. 116-119 (Nov. 2001).
Poller et al., “DNA polymorphisms of the a1-antitrypsin gene region in patients with chronic obstructive pulmonary disease,”European Journal of Clinical Investigation, 20:1-7 (1990).
Rinehart et al., “Human Alpha(1)-Proteinase Inhibitor Binds to Extracellular-Matrix In-Vitro,”American Journal of Respiratory Cell and Molecular Biology, vol. 9, No. 6, pp. 666-679 (Dec. 1993).
Sandford et al, “Mutation in the 3′ region of the α-1 antitrypsin gene and chronic obstructive pulmonary disease,”J. Med. Genet., 34:874-875 (1997).
Sandford et al., “Genetic risk factors for chronic obstructive pulmonary disease,”Eur. Respir. J., 10:1380-1391 (1997).
Shapiro, “Diverse Roles of Macrophage Matrix Metalloproteinases in Tissue Destruction and Tumor Growth,”Thromb Haemost., 82:846-849 (1999).
Sorsa et al., “Doxycycline in the Protection of Serum Alpha-1-Antitrypsin from Human Neutrophil Collagenase and Gelatinase,”Antimicrobial Agents and Chemotherapy, vol. 37, No. 3, pp. 592-594 (1993).
Syrris et al., “Transforming growth factor-β1 gene polymorphisms and coronary artery disease,”Clinical Science, 95:659-667 (1998).
Walter et al., “Environmental and genetic risk factors and gene-environment interactions in the pathogenesis of chronic lung disease,”Environmental Health Perspectives, vol. 108, Suppl. 4, pp. 733-742 (2000).
Ye, S.,Matrix Biologyvol. 19, pp. 623-629 (2000).
Yim et al., “Genetic susceptibility to chronic obstructive pulmonary disease in Koreans: combined analysis of polymorphic genotypes for microsomal epoxide hydrolase and glutathione S-transferase M1 and T1,”Thorax, 55:121-125 (2000).
Zhang et al., “Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12.2-13.1,”Hum. Genet., 105:418-423 (1999).
Zhang et al., “Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary artherosclerosis,”Circulation, vol. 99, pp. 1788-1794 (1999).
U.S. Appl. No. 11/432,736, filed May 10, 2006, Young.
U.S. Appl. No. 11/432,770, filed May 2006.
U.S. Appl. No. 11/438,082, filed May 19, 2006, Young.
U.S. Appl. No. 11/437,823, filed May 19, 2006, Young.
Davis , Wright, Tremaine, LLP
Synergenz Bioscience Limited
Zeman Mark K
LandOfFree
Methods of analysis of polymorphisms and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of analysis of polymorphisms and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of analysis of polymorphisms and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2626800